ARDELYX, INC. Share-based Payment Arrangement, Expense
ARDELYX, INC. (ARDX) reported Share-based Payment Arrangement, Expense of $15.32 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- ARDELYX, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $15.32M, a 31.05% increase year-over-year.
- ARDELYX, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $14.16M, a 17.12% increase year-over-year.
- ARDELYX, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $12.45M, a 26.18% increase year-over-year.
- ARDELYX, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $12.74M, a 39.52% increase year-over-year.
- ARDELYX, INC. share-based payment arrangement, expense for fiscal 2025 was $48.96M, a 30.98% increase from fiscal 2024.
- ARDELYX, INC. share-based payment arrangement, expense for fiscal 2024 was $37.38M, a 176.28% increase from fiscal 2023.
- ARDELYX, INC. share-based payment arrangement, expense for fiscal 2023 was $13.53M, a 25.86% increase from fiscal 2022.
- ARDELYX, INC. share-based payment arrangement, expense for fiscal 2022 was $10.75M, a 10.71% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.32M 10-Q · filed 2026-08-06 | $29.47M 10-Q · filed 2026-08-06 | $41.92M derived: sum of 3 quarters · filed 2026-08-06 | $54.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $14.16M 10-Q · filed 2026-04-30 | $26.60M derived: sum of 2 quarters · filed 2026-04-30 | $39.34M derived: sum of 3 quarters · filed 2026-04-30 | $51.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $12.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $25.19M derived: sum of 2 quarters · filed 2026-02-19 | $36.87M derived: sum of 3 quarters · filed 2026-08-06 | $48.96M 10-K · filed 2026-02-19 |
| 2025-09-30 | $12.74M 10-Q · filed 2025-10-30 | $24.43M derived: sum of 2 quarters · filed 2026-08-06 | $36.52M 10-Q · filed 2025-10-30 | $46.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $11.69M 10-Q · filed 2026-08-06 | $23.77M 10-Q · filed 2026-08-06 | $33.64M derived: sum of 3 quarters · filed 2026-08-06 | $42.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $12.09M 10-Q · filed 2026-04-30 | $21.95M derived: sum of 2 quarters · filed 2026-04-30 | $31.08M derived: sum of 3 quarters · filed 2026-04-30 | $41.85M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $9.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $19.00M derived: sum of 2 quarters · filed 2026-02-19 | $29.77M derived: sum of 3 quarters · filed 2026-02-19 | $37.38M 10-K · filed 2026-02-19 |
| 2024-09-30 | $9.13M 10-Q · filed 2025-10-30 | $19.90M derived: sum of 2 quarters · filed 2025-10-30 | $27.52M 10-Q · filed 2025-10-30 | $31.45M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $10.77M 10-Q · filed 2025-08-04 | $18.39M 10-Q · filed 2025-08-04 | $22.32M derived: sum of 3 quarters · filed 2026-02-19 | $25.80M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $7.62M 10-Q · filed 2025-05-01 | $11.55M derived: sum of 2 quarters · filed 2026-02-19 | $15.04M derived: sum of 3 quarters · filed 2026-02-19 | $18.23M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $3.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $7.42M derived: sum of 2 quarters · filed 2026-02-19 | $10.62M derived: sum of 3 quarters · filed 2026-02-19 | $13.53M 10-K · filed 2026-02-19 |
| 2023-09-30 | $3.49M 10-Q · filed 2024-10-31 | $6.69M derived: sum of 2 quarters · filed 2024-10-31 | $9.60M 10-Q · filed 2024-10-31 | $11.69M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $3.20M 10-Q · filed 2024-08-01 | $6.11M 10-Q · filed 2024-08-01 | $8.20M derived: sum of 3 quarters · filed 2025-02-20 | $10.04M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $2.91M 10-Q · filed 2024-05-02 | $5.00M derived: sum of 2 quarters · filed 2025-02-20 | $6.84M derived: sum of 3 quarters · filed 2025-02-20 | $10.03M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $3.92M derived: sum of 2 quarters · filed 2025-02-20 | $7.12M derived: sum of 3 quarters · filed 2025-02-20 | $10.75M 10-K · filed 2025-02-20 |
| 2022-09-30 | $1.83M 10-Q · filed 2023-10-31 | $5.03M derived: sum of 2 quarters · filed 2023-10-31 | $8.66M 10-Q · filed 2023-10-31 | $12.22M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $3.19M 10-Q · filed 2023-08-02 | $6.82M 10-Q · filed 2023-08-02 | $10.39M derived: sum of 3 quarters · filed 2024-02-22 | $12.65M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $3.72M 10-Q · filed 2023-05-03 | $7.19M derived: sum of 2 quarters · filed 2024-02-22 | $9.46M derived: sum of 3 quarters · filed 2024-02-22 | $12.67M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $3.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $5.73M derived: sum of 2 quarters · filed 2024-02-22 | $8.95M derived: sum of 3 quarters · filed 2024-02-22 | $12.04M 10-K · filed 2024-02-22 |
| 2021-09-30 | $2.26M 10-Q · filed 2022-11-03 | $5.48M derived: sum of 2 quarters · filed 2022-11-03 | $8.57M 10-Q · filed 2022-11-03 | $11.00M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $3.22M 10-Q · filed 2022-08-04 | $6.31M 10-Q · filed 2022-08-04 | $8.74M derived: sum of 3 quarters · filed 2023-03-02 | $11.27M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $3.09M 10-Q · filed 2022-05-05 | $5.52M derived: sum of 2 quarters · filed 2023-03-02 | $8.05M derived: sum of 3 quarters · filed 2023-03-02 | $10.72M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $4.96M derived: sum of 2 quarters · filed 2023-03-02 | $7.63M derived: sum of 3 quarters · filed 2023-03-02 | $10.58M 10-K · filed 2023-03-02 |
| 2020-09-30 | $2.53M 10-Q · filed 2021-11-12 | $5.20M derived: sum of 2 quarters · filed 2021-11-12 | $8.15M 10-Q · filed 2021-11-12 | $10.36M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $2.67M 10-Q · filed 2021-08-13 | $5.62M 10-Q · filed 2021-08-13 | $7.83M derived: sum of 3 quarters · filed 2022-02-28 | $11.71M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $2.95M 10-Q · filed 2021-05-06 | $5.16M derived: sum of 2 quarters · filed 2022-02-28 | $9.04M derived: sum of 3 quarters · filed 2022-02-28 | $10.96M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $6.09M derived: sum of 2 quarters · filed 2022-02-28 | $8.01M derived: sum of 3 quarters · filed 2022-02-28 | $9.94M 10-K · filed 2022-02-28 |
| 2019-09-30 | $3.88M 10-Q · filed 2020-11-05 | $5.80M derived: sum of 2 quarters · filed 2020-11-05 | $7.72M 10-Q · filed 2020-11-05 | $9.97M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-06-30 | $1.92M 10-Q · filed 2020-08-06 | $3.85M 10-Q · filed 2020-08-06 | $6.09M derived: sum of 3 quarters · filed 2021-03-08 | $8.04M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-03-31 | $1.92M 10-Q · filed 2020-05-07 | $4.17M derived: sum of 2 quarters · filed 2021-03-08 | $6.12M derived: sum of 3 quarters · filed 2021-03-08 | $8.72M derived: sum of 4 quarters · filed 2021-03-08 |
| 2018-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $4.20M derived: sum of 2 quarters · filed 2021-03-08 | $6.80M derived: sum of 3 quarters · filed 2021-03-08 | $9.23M 10-K · filed 2021-03-08 |
| 2018-09-30 | $1.95M 10-Q · filed 2019-11-06 | $4.55M derived: sum of 2 quarters · filed 2019-11-06 | $6.98M 10-Q · filed 2019-11-06 | $9.56M derived: sum of 4 quarters · filed 2020-03-06 |
| 2018-06-30 | $2.60M 10-Q · filed 2019-08-09 | $5.03M 10-Q · filed 2019-08-09 | $7.62M derived: sum of 3 quarters · filed 2020-03-06 | $9.72M derived: sum of 4 quarters · filed 2020-03-06 |
| 2018-03-31 | $2.42M 10-Q · filed 2019-05-07 | $5.01M derived: sum of 2 quarters · filed 2020-03-06 | $7.12M derived: sum of 3 quarters · filed 2020-03-06 | $9.91M derived: sum of 4 quarters · filed 2020-03-06 |
| 2017-12-31 | $2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | $4.69M derived: sum of 2 quarters · filed 2020-03-06 | $7.48M derived: sum of 3 quarters · filed 2020-03-06 | $9.59M 10-K · filed 2020-03-06 |
| 2017-09-30 | $2.10M 10-Q · filed 2018-11-07 | $4.89M derived: sum of 2 quarters · filed 2018-11-07 | $7.00M 10-Q · filed 2018-11-07 | $8.55M derived: sum of 4 quarters · filed 2019-03-06 |
| 2017-06-30 | $2.79M 10-Q · filed 2018-08-07 | $4.90M 10-Q · filed 2018-08-07 | $6.45M derived: sum of 3 quarters · filed 2019-03-06 | $7.74M derived: sum of 4 quarters · filed 2019-03-06 |
| 2017-03-31 | $2.11M 10-Q · filed 2018-05-08 | $3.66M derived: sum of 2 quarters · filed 2019-03-06 | $4.95M derived: sum of 3 quarters · filed 2019-03-06 | $6.24M derived: sum of 4 quarters · filed 2019-03-06 |
| 2016-12-31 | $1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $2.84M derived: sum of 2 quarters · filed 2019-03-06 | $4.13M derived: sum of 3 quarters · filed 2019-03-06 | $5.32M 10-K · filed 2019-03-06 |
| 2016-09-30 | $1.29M 10-Q · filed 2017-11-07 | $2.58M derived: sum of 2 quarters · filed 2017-11-07 | $3.77M 10-Q · filed 2017-11-07 | $4.53M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $1.29M 10-Q · filed 2017-08-09 | $2.48M 10-Q · filed 2017-08-09 | $3.23M derived: sum of 3 quarters · filed 2018-03-14 | $3.95M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $1.19M 10-Q · filed 2017-05-05 | $1.95M derived: sum of 2 quarters · filed 2018-03-14 | $2.66M derived: sum of 3 quarters · filed 2018-03-14 | $3.30M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | $757.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $1.47M derived: sum of 2 quarters · filed 2018-03-14 | $2.11M derived: sum of 3 quarters · filed 2018-03-14 | $2.63M 10-K · filed 2018-03-14 |
| 2015-09-30 | $712.00K 10-Q · filed 2016-11-07 | $1.35M derived: sum of 2 quarters · filed 2016-11-07 | $1.88M 10-Q · filed 2016-11-07 | $3.08M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $641.00K 10-Q · filed 2016-08-08 | $1.17M 10-Q · filed 2016-08-08 | $2.37M derived: sum of 3 quarters · filed 2017-02-17 | $2.69M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $524.00K 10-Q · filed 2016-05-09 | $1.73M derived: sum of 2 quarters · filed 2017-02-17 | $2.05M derived: sum of 3 quarters · filed 2017-02-17 | $2.15M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $1.53M derived: sum of 2 quarters · filed 2017-02-17 | $1.63M derived: sum of 3 quarters · filed 2017-02-17 | $1.69M 10-K · filed 2017-02-17 |
| 2014-09-30 | $322.00K 10-Q · filed 2015-11-12 | $421.00K derived: sum of 2 quarters · filed 2015-11-12 | $484.00K 10-Q · filed 2015-11-12 | |
| 2014-06-30 | $99.00K 10-Q · filed 2015-08-12 | $163.00K 10-Q · filed 2015-08-12 | ||
| 2014-03-31 | $64.00K 10-Q · filed 2015-05-12 | |||
| 2013-12-31 | $352.00K 10-K · filed 2016-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |